Home LifestyleHealth U.S. officials say two coronavirus vaccines may be available to the public before Christmas.
Coronavirus outbreak in a prison in Thailand 112 people were diagnosed with COVID-19

U.S. officials say two coronavirus vaccines may be available to the public before Christmas.

by YCPress

Washington, November 30 In an interview with the U.S. media on November 30, Alex Aza, the U.S. Secretary of Health and Human Services said that if the emergency use authorization application for the relevant coronavirus vaccine is approved, the United States may provide two coronavirus vaccines to the public before Christmas.

Aza said that the FDA’s external advisory team will consider the emergency authorization application for the use of the coronavirus vaccine submitted by Pfizer Pharmaceutical Co., Ltd. on December 10. If everything goes well, the application may be approved within a few days. In addition, the U.S. Modner’s coronavirus vaccine may be approved a week later than Pfizer’s vaccine. The vaccine will begin to be distributed to the United States within 24 hours of approval.

Aza said that the federal government will ship vaccines through its normal vaccine distribution system, and state governors are responsible for determining where the vaccine will be sent first and which groups of people are prioritized for vaccination. The CDC will advise which groups are prioritized for vaccination.

The coronavirus vaccine jointly developed by Pfizer and German biotechnology company is an mRNA (messenger ribonucleic acid) vaccine. The two companies announced on November 18 that the results of phase 3 clinical trials showed that the vaccine was effective in preventing COVID-19 infection by 95%. On November 20, the two companies submitted an emergency use authorization application to the U.S. Drug Administration.

The COVID-19 vaccine developed by Modena in cooperation with the National Institute of Allergy and Infectious Diseases is also an mRNA vaccine. Modena issued a statement on November 30 that the results of the phase 3 clinical trial showed that the vaccine was effective in preventing COVID-19 infection by 94.1%, and the company planned to submit an emergency use authorization application to the U.S. Drug Administration on the same day.